Hereditary breast/ovarian cancer is a well-characterized clinical entity, largely attributed to the inheritance of BRCA1 or BRCA2 mutations. Among general population, the mutation's frequency of these genes is very low; therefore, the identification of two independent mutations in the same family is a rare event. This study reports the presence of two mutations, one in the BRCA1 and the second in the BRCA2 gene in an Italian Caucasian kindred. This family is composed of more than 250 individuals, spanning through five generations, among which endogamy was a common phenomenon. Considering the tumor spectrum, this family is characterized by a high incidence of different types of cancer. In our study, we considered only three out of seven family units for BRCA1 and BRCA2 analysis. In one of the family units, we found independent mutations of both BRCA genes. The BRCA1 mutation on exon 11 (3358T-A) was identified originally in the index case and subsequently in 18 members of this family, whereas the same mutation was not detected in a related family member with male breast cancer. The male breast cancer patient led to the identification, through mutational analysis, of a new BRCA2 mutation (8756delA). This BRCA2 mutation was also found in the male breast cancer patient's daughter. The discovery of the BRCA2 mutation allowed us to alert the patient's daughter who, otherwise, could be falsely reassured since she had a negative BRCA1 test.
Introduction
The detection of two independent mutations in both the breast/ovarian cancer susceptibility genes, BRCA1 and BRCA2, is rarely described among the members of the same family. Until now, these mutations were found together in Ashkenazi Jewish kindred [1] [2] [3] [4] [5] [6] and in a few cases of non-Jewish families. [7] [8] [9] It has to be pointed out that independent BRCA1 and BRCA2 mutations have never been detected before in Italian families. We described an extended Italian family where two different non-Ashkenazi Jewish mutations, one in the BRCA1 and the second in the BRCA2 gene, are present in independent members of this family. The two mutations described in the present report have never been observed in the same individual. The genetic testing for BRCA1 and BRCA2 was performed by direct automated sequencing (DAS) in 38 members. In this family, we found this BRCA1 mutation in 19 members, six affected and 13 healthy, and a BRCA2 novel mutation only in a male breast cancer patient and in his healthy daughter.
The identification of these independent BRCA1 and BRCA2 mutations in the same family, represents the first report in a pedigree not belonging to the Ashkenazi Jewish population and could reflect the possibility of a 'de novo' BRCA2 mutation.
Materials and methods

Family
This five-generation family named M019 (Figure 1) 
Statistical methods
Standardized incidence ratios (SIRs) were calculated by determining the ratio of the observed patients compared to the expected number of cases with all the breast and ovarian cancers. The end point for person-years calculation was 31 December 2000 or the date of diagnosis of the sitespecific neoplasm under investigation or, the date of death or emigration when appropriate. The expected number of subjects with cancer was determined by using 5-year age, sex and calendar-period specific incidence rates estimated for the Modena province population. 13 As a whole, the incidence of breast and ovarian cancers was considerably higher than expected (Table 2) .
Results
In all, 38 members of this family were analyzed with DAS for BRCA1 and BRCA2 mutations. We found the 3358T-A Figure 1 , Ovarian, and , Breast UNI; , Breast BI, and , Others. Pedigree showing the incidence of cancer as well as BRCA1 and BRCA2 mutation carrier status in the descendants of the three family units studied named 2:2, 2:4, 2:5. BRCA1-11 ¼ 3358T-A; BRCA2-20 ¼ 8756delA; WT ¼ wild type.
A family carrying BRCA1 and BRCA2 gene mutations L Cortesi et al BRCA1 nonsense mutation in three patients with breast cancer, two patients with ovarian cancer and one patient with uterine adenocarcinoma. Furthermore, 13 healthy individuals were carriers of the same BRCA1 mutation.
Since the male breast cancer patient was BRCA1 negative and considering the high incidence of BRCA2 mutations in families with male breast cancer, 14 we performed mutational analysis for the BRCA2 gene on this patient. As a consequence, we detected a BRCA2 mutation on exon 20, characterized by 8756delA, giving rise to a stop codon insertion at nucleotide 8815 causing a truncated protein product. This mutation had never been identified before and was found also in the patient's healthy daughter.
Moreover, all the members tested for BRCA1 analysis were also searched for the 8756delA BRCA2 mutation, but we did not find any additional carrier. One BRCA1 female breast cancer patient had an in situ ductal carcinoma at 43 years of age (4:21 in Figure 1 ), whereas two other patients (3:5, 4:12) were characterized by ductal infiltrating carcinoma with an aggressive phenotype: grading III, hormonal receptors negative, high proliferation rate. 12 All the four BRCA1 ovarian cancers 
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The male breast cancer (3:27) was a poorly differentiated, infiltrating ductal carcinoma. To evaluate the frequency of this novel deletion in BRCA2 gene, we analyzed 10 other cases of male breast cancer belonging to unrelated families. All the cases studied were negative for this mutation.
Furthermore, in our family where the ratio between ovarian and breast cancers is almost 1:1, the results are in accordance with the literature data. The relative risk for breast and ovarian cancer is also similar, being the SIR (see Table 2 ) 25.7 for BC and 24.1 for OC. It has to be considered that the high SIR of the other tumors (AC ¼ 14.6) could reflect an involvement of 3358T-A BRCA1 mutation in different types of tumors. The high cancer risk in this Italian family is therefore consistent with the studies of Ludwig et al 10 and Thompson et al for the Breast Cancer Linkage Consortium. 16 
Discussion
In this study, we describe an atypical Italian family characterized by a large number of individuals and by endogamy among family members. This family shows two separate mutations segregating with breast and ovarian cancer, among multiple siblings. Our family shares many characteristics with the large kindred of Ashkenazi Jewish, in which BRCA1 and BRCA2 mutations are frequently detected. The 3358T-A BRCA1 mutation is certainly inherited since 50% of the members of the three family units studied are carriers. Since only the male breast cancer patient and his daughter were found positive for BRCA2 mutational analysis, the most probable interpretation is that this is a 'de novo' mutation. We cannot exclude the possibility that the mutation was inherited from the father or the mother or any maternal relative, since archival tumor tissue of the parents is not available. Another possibility is that the male breast case with the BRCA2 mutation might have a different father from the others. Furthermore, other male breast cancer patients, belonging to unrelated families, are negative for this specific mutation while they are positive for other recurrent BRCA2 mutations, such as 6174delT and 9326insA. The biopathological parameters of this BRCA2 cancer show an aggressive tumor phenotype and this is in contrast with the literature data characterizing other kinds of mutations.
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This study revealed the importance and the benefit deriving from the knowledge of an accurate family history in the context of genetic testing. In fact, the lack of information about the male breast cancer of individual 3:27, would have made it impossible to identify the second mutation and, moreover, it would have been misleading for the patient's daughter, negative for BRCA1 but resulting positive for BRCA2. The 3358T-A BRCA1 mutation was reported, for the first time, by Gayther et al 18 in a family characterized by one ovarian and seven breast cancers. It was the only mutation, located in the first two-thirds of the coding sequence, where the breast cancer is higher than the ovarian cancer incidence. Further studies have shown that the frequency of ovarian cancer compared to breast cancer associated with mutations downstream to the granin motif (nucleotides 3760-3787) was significantly lower than for other mutations. 19 Our data are in agreement with those of Thompson et al 20 that, evaluating the genotype-phenotype correlations in 356 families with BrCa1 mutations, demonstrated that the mutations occurring in the regions 2401-4190 are more frequently involved in the development of ovarian cancer rather than those mapping at nucleotides 1-2400. Our findings suggest that the BRCA1 3358T-A mutation predisposes also to a high incidence of ovarian cancer with the consequence that the surveillance strategies must be different and, particularly, we believe appropriate to consider a prophylactic oophorectomy for the carrier. Although our data show that there is an elevated cancer risk for this family, the results do not allow us to draw conclusions on tumor types other than breast and ovarian cancer. 
